<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101382</url>
  </required_header>
  <id_info>
    <org_study_id>IFOM-CPO006/2019/PO005</org_study_id>
    <nct_id>NCT05101382</nct_id>
  </id_info>
  <brief_title>A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)</brief_title>
  <acronym>ALFAOMEGA-R</acronym>
  <official_title>A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IFOM, The FIRC Institute of Molecular Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IFOM, The FIRC Institute of Molecular Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALFAOMEGA-RETRÒ will be exploited to retrospectively collect clinical and imaging data and&#xD;
      archival samples to be used for validation and correlative studies on markers discovered by&#xD;
      cutting-edge translational projects within the AIRC5x1000 program &quot;Insights into the evolving&#xD;
      heterogeneity of colorectal cancer (CRC): from mechanism to therapies&quot; (an ongoing&#xD;
      multi-institutional research program).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALFAOMEGA-RETRÒ, the retrospective &quot;mirror&quot; protocol of ALFAOMEGA (protocol n.&#xD;
      IFOM-CPO003/2018/PO002), has been designed to build a retrospective collection of clinically&#xD;
      annotated data and biological samples retrieved from colorectal cancer patients (CRC).&#xD;
&#xD;
      The repository will feed experimental precision research aimed at i) defining a new taxonomy&#xD;
      of CRC based on evolutionary patterns (retrospectively assessed on patient's samples), ii)&#xD;
      developing and evaluating innovative biomarker-specific therapeutic strategies derived from&#xD;
      or together with ALFAOMEGA.&#xD;
&#xD;
      The following data and biological samples will be collected:&#xD;
&#xD;
        -  Clinical Data (Demographics, Medical History, Cancer Diagnosis &amp; History, Treatment&#xD;
           Assessment,).&#xD;
&#xD;
        -  Imaging Data (CT-Scans, MRI, PET...).&#xD;
&#xD;
        -  Formalin-Fixed Paraffin-Embedded (FFPE) tissue (either from surgical resections or&#xD;
           diagnostic biopsies).&#xD;
&#xD;
        -  Frozen biological samples (blood, plasma, PBMC, stools, buccal swabs, urines, etc.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of retrospectively recruited CRC cases</measure>
    <time_frame>6 months</time_frame>
    <description>Number of retrospectively recruited CRC cases with complete matched clinical data, radio-imaging data and FFPE or frozen biological samples.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of new prognostic and predictive markers</measure>
    <time_frame>6 months</time_frame>
    <description>Number of identified/validated new independent prognostic and predictive biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers correlation with PFS</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of new prognostic and predictive biomarkers with progression-free survival (PFS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers correlation with OS</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of new prognostic and predictive biomarkers with overall survival (OS).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort of CRC patients</arm_group_label>
    <description>Stage-mixed cohort of at least 500 CRC patients that cannot be reached for informed consent (death or lost-to-follow-up)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Retrospective Observation of standard clinical practice</description>
    <arm_group_label>Cohort of CRC patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE tissue Frozen biological samples (whole blood, plasma, PBMC, stools, buccal swabs,&#xD;
      urines)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        at least 500 colorectal cancer patients at any stage who cannot be reached for an informed&#xD;
        consent&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed diagnosis of colorectal cancer (any stage).&#xD;
&#xD;
          -  Age &gt;18 years at the time of diagnosis.&#xD;
&#xD;
          -  Availability of clinically-annotated radio-imaging data and/or diagnostic&#xD;
             Formalin-Fixed Paraffin Embedded (FFPE) blocks (surgical resections and/or tumor&#xD;
             biopsies), or at least 10 slides (preferably 20). FFPE tissue blocks are always&#xD;
             preferred to slides.&#xD;
&#xD;
          -  Verification that the patient could not be reached for informed consent in accordance&#xD;
             with applicable national regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  if inclusion criteria are not met&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Marsoni, MD</last_name>
    <role>Study Director</role>
    <affiliation>IFOM, The FIRC Institute of Molecular Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niguarda Cancer Center - ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto (IOV)</name>
      <address>
        <city>Padua</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - IRCCS</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar - Parc de Salut Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institute of Oncology (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INCLIVA - Instituto de Investigatión Sanitaria</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>CRC</keyword>
  <keyword>Gastrointestinal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

